Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT04179175

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Conditions: Hidradenitis Suppurativa

Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 702
Sponsor: Novartis Pharmaceuticals

Location: Northwest Arkansas Center Rogers Arkansas

Summary

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).

Eligibility Criteria

Inclusion Criteria: * written informed consent must be obtained before any assessment is performed * subject must have completed the study treatment period (52 weeks) in the core studies (AIN457M2301 or AIN457M2302) and had received secukinumab treatment during Treatment Period 2 Exclusion Criteria: * protocol deviation in the core study which will prevent the meaningful analysis of the extension study * ongoing or planned use of prohibited HS or non-HS treatment * participation in the extension could expose the subject to an undue safety risk * current sever progressive or uncontrolled disease which renders the subject unsuitable for the study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04179175). StuddyBuddy aggregates publicly available trial information.